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T he coronavirus disease 2019 (COVID-19) pandemic(caused by severe acute respiratory syndrome corona-virus 2 [SARS-CoV-2]) has led to a dramatic loss of
lives and presented an unprecedented challenge to public
health and economic systems worldwide. To date, >58.7
million people globally have been infected with the SARS-
CoV-2 virus, and >1.39 million individuals have died
(https://covid19.who.int/, last accessed November 24, 2020).
Among patients with chronic illness, including patients
with kidney failure and those with kidney transplants, the
impact is even more substantial. The estimated incidence of
SARS-CoV-2 infection and COVID-19 in patients on dialysis
and with kidney transplants exceeds that of the general popu-
lation by as much as 15-fold.1 The risk of complications and
death associated with COVID-19 is also considerably higher
among kidney transplant recipients.2 Reasons for the observed
differences between transplant recipients and the general pop-
ulation may be attributed to multiple comorbidities, and the
suppressed immune system in these vulnerable patients.
Sex as a risk factor for COVID-19 infection and outcomes in
transplant recipients
Sex (a biologically determined variable defined by genetics,
hormones, and anatomy) may impact outcomes in kidney
transplantation and may also affect survival from SARS-CoV-2
infection and COVID-19. The incidence of COVID-19 in the
general population is overall similar between the sexes, with sex
variation within different countries possibly reflecting differ-
ential sex-biased access to testing. Likewise, accounting for the
higher proportion of transplant recipients who are male, the
incidence of COVID-19 after kidney transplantation also ap-
pears to be similar in both sexes.1 However, after controlling
for age and comorbidities, COVID-19–attributable mortality
rates in the general population are 1.5-fold to 2.0-fold higher in
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males than females.3 In contrast, although kidney trans-
plantation has been associated with as much as a 10-fold higher
mortality with COVID-19 compared with the general popu-
lation,2 no consistent sex differences in COVID-19–related
mortality have been observed in kidney transplant recipients.1
Although sex differences in case fatality rates in the transplant
population may emerge as more data accumulate, the apparent
lack of sex differences in case fatality rates in transplant patients
to date may reflect sex-related differences in the effects of
immunosuppression.
Mechanistic pathways of sex differences in COVID-19
outcomes in transplant recipients
SARS-CoV-2 infection has 2 distinct phases: initial viral
infection and subsequent systemic inflammatory and endo-
thelial responses. The immune dysregulation by SARS-CoV-2
infection may be a consequence of the zoonotic origin of this
virus, and therefore, sex differences may be more prominent
compared with other infections. In general, females generate a
greater innate and adaptive antiviral immune response than
males, owing in part to estrogens increasing T-cell and anti-
body responses, and to the potential for females to express
greater numbers of X-linked immune-related genes due to
incomplete X-inactivation.4 Therefore, immunocompetent
females may demonstrate enhanced local clearance of viruses
when compared with males (Figure 1).4 Conversely, SARS-
CoV-2 clearance may be relatively impaired in males, in
part due to the immune-suppressing properties of testos-
terone. As testosterone levels decline in older age, however,
males begin to experience more dysregulated innate immu-
nity and inflammatory pathology (“inflamm-aging”)3 as well
as reduced adaptive immunity compared with age-matched
females. These findings correspond with the higher likeli-
hood among older immunocompetent males than females of
a catastrophic dysregulated immune response to COVID-19
(i.e., “cytokine storm”) and death. Emerging evidence sug-
gests a potential role for type I interferons in protecting
against SARS-CoV-2 infection, with patients having neutral-
izing anti-interferon autoantibodies experiencing more severe
disease. Although, in general, autoimmunity is more
frequently observed in females, autoantibodies against type I
interferon have been shown to be more common in SARS-
CoV-2 infected males.5 In the transplant population, immu-
nosuppression may lead to decreased viral clearance.4 Yet, at
the same time, immunosuppression may paradoxically pro-
tect against fatal immune dysregulation in the second phase of
infection. The significantly lower 28-day mortality in patients
with severe COVID-19 courses treated with dexamethasone
in the Randomised Evaluation of COVID-19 Therapy (RE-
COVERY) trial6 supports this notion. Interestingly, although
the interaction between sex and steroid therapy did not reach
statistical significance, the survival benefit demonstrated with
dexamethasone was primarily observed in males. The
apparent lack of a higher COVID-19–related mortality risk in
male than female transplant recipients may be similarly
explained by the effect of maintenance immunosuppression
dampening down the dysregulated inflammatory effects
observed more commonly in immunocompetent males than
Figure 1 | The roles of sex, gender, and transplantation in coronavirus disease 2019 (COVID-19). ACE2, angiotensin-converting enzyme
2; PD, pharmacodynamics; PG, pharmacogenomics; PK, pharmacokinetics; TLR, toll-like receptor; TMPRSS2, transmembrane protease serine 2.
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females. Calcineurin inhibitors, the cornerstone of mainte-
nance immunosuppressive therapy in transplant patients, are
also being explored for their potential action against SARS-
CoV-2 infection through inhibition of the immunophilin
pathway (https://clinicaltrials.gov/ct2/show/NCT04341038).
Sex differences in the pharmacokinetics and possibly the
pharmacodynamics of calcineurin inhibitors might
contribute to the comparable COVID-19 mortality rates
observed in male and female transplant recipients. These sex
differences emphasize the need for clinical trials that allow
sex-stratified analyses.
Gender, COVID-19, and transplantation
In addition to determining the impact of biologic sex on
response to viral infection, it is also important to consider
the role of gender (Figure 1)—a sociocultural construct
relating to identities, norms, and behaviors—on viral
exposure, access to care, and social impacts. Gender differ-
ences in risk and self-management behavior may have also
contributed to the observed differences in survival by
gender. People who identify as masculine may be more likely
to smoke, may be more likely to display worse hand hygiene,
and tend to be less health care seeking than individuals who
identify as feminine. Conversely, individuals engaged in
traditionally feminine occupations, like frontline health care
workers and caregivers for the ill, are at a heightened risk for
viral exposure. During the pandemic, women have been more
likely to become unemployed, resulting in differential eco-
nomic hardships for men and women.7 Furthermore, longer
time at home due to social distancing and isolation measures
has placed some people in vulnerable situations, with women
being at a greater risk for experiencing domestic violence.
Importantly, although individuals who identify as women are
more likely to seek medical attention, they are less likely to
be offered diagnostic testing and evidence-based treatment
interventions than are those identifying as men.8
Although data in the transplant population are lacking,
patients with rheumatic disease, many of whom are immu-
nosuppressed, were nearly twice as likely to adhere to strict
social distancing recommendations than were healthy con-
trols. Likewise, one might expect that when contrasted with
the general population, male transplant patients may be less
vulnerable to the impacts of masculinity, as represented by
behavioral choices due to a heightend awareness of their
suppressed immune status and associated risks of contracting
infections. Whether male transplant patients are more likely
than male patients in the general population to participate in
preventive strategies, adhere to social distancing, and exercise
better hand hygiene requires further study.
Policy and research implications of COVID-19 in transplant
recipients
The comparable mortality rates between male and female kidney
transplant recipients may represent a relatively better survival in
transplanted males in contrast to the male-biased mortality risk
observed in the general population. Thus, thoughtful consider-
ation of the impact of sex and gender on the pathogenesis, diag-
nosis, treatment, and prevention of COVID-19 in kidney
transplant recipients has the potential to benefit personalized care
and improve outcomes among transplant recipients. It is critical
that future research allows for sex-disaggregated analyses in both
observational and interventional studies. There are data to suggest
a protective effect of endogenous estrogens on the immune
response to the SARS-CoV-2 virus.7 Therefore, given the impact
of age on levels of circulating sex hormones, it is also important
that future research consider thepotentialmodifying effects of age.
Moreover, information regarding menopausal status and exoge-
nous hormone replacement therapy (in cisgender and trans-
gender individuals) may also be relevant and must be sought.
Early observations regarding sex differences in COVID-19
outcomes are important in the development of future preven-
tive and treatment strategies. Females generally display superior
vaccine efficacy compared with males but a higher rate of
vaccine-related adverse outcomes.4 Among the list of promising
drugs against COVID-19, historical data have shown that
females may have a higher risk for medication-related compli-
cations than males, likely related to sex-mediated differences in
pharmacokinetics, pharmacodynamics, body mass and
Figure 2 | Summary of proposed policy changes, targeted stakeholders, and benefits to the individual patient.
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composition, and drug bioavailability.9 For example, females are
known to experience more hydroxychloroquine-associated QT
prolongation and fatal ventricular arrhythmias than males.7
Although this therapy has been explored in clinical trials for
the treatment of SARS-CoV-2 infection and COVID-19, no sex-
stratified analyses have been planned. This risk may be further
exaggerated in the setting of standard maintenance immuno-
suppressive therapy among transplant recipients as calcineurin
inhibitors may further potentiate QT prolongation. Also, fe-
males may demonstrate an attenuated response to certain drugs,
such as colchicine,7 which is being evaluated for the treatment of
advanced COVID-19 in the large-scale Colchicine Coronavirus
SARS-CoV2 Trial (COLCORONA; https://clinicaltrials.gov/ct2/
show/NCT04322682). However, current and ongoing COVID-
19 trials have not ensured sex-disaggregated data collection.
More important, sex was not included as a stratifying variable
during the randomization process. In clinical trials and obser-
vational studies, the lack of assessment and the lack of reporting
on the impact of sex as intervention modifiers have posed major
impediments in understanding the biology of sex differences in
response to treatments. Females have also been traditionally
underrepresented in randomized controlled trials, and only a
minority of COVID-19–related clinical trials include equal
representation of both sexes. We strongly recommend that the
potential impact of sex on vaccine responses and on specific
drug-drug interactions, especially in immunosuppressed pa-
tients, requires consideration when designing clinical trials.
No less important is evaluation of the role gender may play
in outcomes relating to SARS-CoV-2 infection. Transplant
patients represent a vulnerable population experiencing a
high comorbidity burden, warranting more rigorous social
distancing than the general population, which also impacts
access of these patients to services and limits their return to
work. This might affect individuals identifying as women and
men differently. COVID-19 introduces a novel stressor to the
health care system, which may lead to delays in the provision
of routine or scheduled care related to recipient and/or living-
donor assessment and transplantation surgery. Operations
may be delayed, potentially impacting the prospects of sur-
vival and/or morbidity on the waiting list, which can also
differ by sex. There is a need for tailored preventive strategies
that are sex and gender sensitive. Globally, women make up
>70% of health and social frontline workers, such as nurses,
midwives, social workers, cleaners, and laundry workers. We
need equitable strategies that specifically address the social
and economic impact of COVID-19 and support women
within the health sector to build resilience and independence
in managing their own health during this pandemic. Policy-
makers also need to take this gender divide into account to
guarantee the safety, recognition, and support of essential
health care workers involved in the care of patients with
kidney disease and transplantation. This includes ensuring
adequate access to personal protective equipment that ac-
commodates both male and female anatomical differences
and user preference. Finally, testing for COVID-19 and sex-
stratified evidence-based treatments must be offered equally
to men and women. A selection of policy considerations,
targeted stakeholders, and the potential benefits to kidney
transplant patients is shown in Figure 2.
In conclusion, differences in sex- and COVID-19–related
mortality between kidney transplant recipients and the gen-
eral population may enhance our evolving understanding of
COVID-19 pathophysiology and disease management. Bio-
logical sex differences impact the incidence of infection, dis-
ease course, and treatment; these may be further modulated
by gendered factors, affecting exposure and participation in
care. The health crisis precipitated by COVID-19 forces us to
consider the impact of sex and gender in our transplant pa-
tients. Even when COVID-19 is brought under control,
stepping up to the challenge of providing tailored care for
individual kidney transplant patients requires continued
consideration of sex and gender in study design, conduct,
analysis, and reporting of fundamental as well as observa-
tional and interventional clinical research.
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